A comparison of medicines used for overactive bladder (fesoterodine vs mirabegron vs solifenacin)

A comparative study of fesoterodine vs mirabegron vs solifenacin in cases of overactive bladder. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063069

Enrollment

Registered

2024-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N328- Other specified disorders of bladder

Interventions

Intervention1: FESOTERODINE: 8 mg twice a day per oral for 15 days Intervention2: MIRABEGRON: 50 mg twice a day per oral for 15 days Intervention3: SOLIFENACIN: 10 mg twice a day per oral for 15 days

Eligibility

Inclusion criteria

Inclusion criteria: All cases of overactive bladder undergoing treatment at Dr. PSIMS and RF hospital

Exclusion criteria

Exclusion criteria: Patients not willing to participate in the study Patients lost to follow up Patients less than 18 years of age

Design outcomes

Primary

Measure	Time frame
Improvement in OABSS scoreTimepoint: 1 month	—

Secondary

Measure	Time frame
Significant side effectsTimepoint: 15 days	—

Countries

India

Contacts

Public ContactDr. P. Bala Murali Krishna

DR PSIMS and RF, VIJAYAWADA

sainathjsd@yahoo.co.in6351827300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026